The use of large language models to enhance cancer clinical trial educational materials
Open Access
- 8 February 2025
- journal article
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 9 (2)
Abstract
Background: Adequate patient awareness and understanding of cancer clinical trials is essential for trial recruitment, informed decision making, and protocol adherence. Although large language models (LLMs) have shown promise for patient education, their role in enhancing patient awareness of clinical trials remains unexplored. This study explored the performance and risks of LLMs in generating trial-specific educational content for potential participants. Methods: Generative Pretrained Transformer 4 (GPT4) was prompted to generate short clinical trial summaries and multiple-choice question-answer pairs from informed consent forms from ClinicalTrials.gov. Zero-shot learning was used for summaries, using a direct summarization, sequential extraction, and summarization approach. One-shot learning was used for question-answer pairs development. We evaluated performance through patient surveys of summary effectiveness and crowdsourced annotation of question-answer pair accuracy, using held-out cancer trial informed consent forms not used in prompt development. Results: For summaries, both prompting approaches achieved comparable results for readability and core content. Patients found summaries to be understandable and to improve clinical trial comprehension and interest in learning more about trials. The generated multiple-choice questions achieved high accuracy and agreement with crowdsourced annotators. For both summaries and multiple-choice questions, GPT4 was most likely to include inaccurate information when prompted to provide information that was not adequately described in the informed consent forms. Conclusions: LLMs such as GPT4 show promise in generating patient-friendly educational content for clinical trials with minimal trial-specific engineering. The findings serve as a proof of concept for the role of LLMs in improving patient education and engagement in clinical trials, as well as the need for ongoing human oversight.Keywords
All Related Versions
Funding Information
- Woods Foundation (NIH R01CA294033)
This publication has 49 references indexed in Scilit:
- Perspectives on Artificial Intelligence–Generated Responses to Patient MessagesJAMA Network Open, 2024
- AI-Generated Clinical Summaries Require More Than AccuracyJAMA, 2024
- Large Language Model−Based Chatbot vs Surgeon-Generated Informed Consent Documentation for Common ProceduresJAMA Network Open, 2023
- Use of Artificial Intelligence Chatbots for Cancer Treatment InformationJAMA Oncology, 2023
- Diversity in Clinical Trial Enrollment and Reporting—Where We Are and the Road AheadJAMA Cardiology, 2023
- Growth in eligibility criteria content and failure to accrue among National Cancer Institute (NCI)‐affiliated clinical trialsCancer Medicine, 2022
- Barriers for cancer clinical trial enrollment: A qualitative study of the perspectives of healthcare providersContemporary Clinical Trials Communications, 2022
- Increasing Diversity in Clinical Trials: Overcoming Critical BarriersCurrent Problems in Cardiology, 2019
- Consent in clinical trials: What do patients know?Contemporary Clinical Trials, 2010
- Participation in Cancer Clinical TrialsJAMA, 2004